Sojourn Use In Pregnancy & Lactation

Pregnancy: Pregnancy Category B: Reproduction studies have been performed in rats and rabbits at doses up to 1 MAC (minimum alveolar concentration) without CO₂ absorbent and have revealed no evidence of impaired fertility or harm to the fetus due to sevoflurane at 0.3 MAC, the highest nontoxic dose. Development and reproductive toxicity studies of sevoflurane in animals in the presence of strong alkalies (i.e., degradation of sevoflurane and production of Compound A) have not been concluded. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, sevoflurane should be used during pregnancy only if potential benefit outweighs the risk.
Labor and Delivery: Sevoflurane has been used as part of general anesthesia for elective cesarean section 29 women. There were no untoward effects in mother or neonate. (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions). The safety of sevoflurane in labor and delivery has not been demonstrated.
Lactation: Because of rapid washout, sevoflurane concentrations in milk are predicted to be below those found with many other volatile anesthetics. Caution should be exercised when the drug was administered to nursing mothers.